PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 213 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.61 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $60,912,000 | +250.1% | 1,600,000 | +300.0% | 2.54% | +322.8% |
| Q2 2019 | $17,396,000 | +14.3% | 400,000 | 0.0% | 0.60% | -8.7% |
| Q1 2019 | $15,224,000 | -11.5% | 400,000 | 0.0% | 0.66% | -36.1% |
| Q4 2018 | $17,208,000 | -15.3% | 400,000 | -3.2% | 1.03% | +10.3% |
| Q3 2018 | $20,309,000 | -56.6% | 413,196 | -71.7% | 0.93% | -48.2% |
| Q2 2018 | $46,813,000 | -12.4% | 1,460,610 | -14.8% | 1.80% | -29.4% |
| Q1 2018 | $53,424,000 | +37.9% | 1,715,072 | +102.1% | 2.55% | +1.6% |
| Q4 2017 | $38,737,000 | -21.3% | 848,572 | -35.3% | 2.51% | -34.3% |
| Q3 2017 | $49,245,000 | +121.6% | 1,311,460 | +181.5% | 3.82% | +36.1% |
| Q2 2017 | $22,220,000 | +18.8% | 465,818 | +13.6% | 2.81% | +17.5% |
| Q1 2017 | $18,696,000 | – | 410,000 | – | 2.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
| Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
| GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
| Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
| Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
| Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
| Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |